Differences in characteristics between healthcare-associated and community-acquired infection in community-onset *Klebsiella pneumoniae* bloodstream infection in Korea

Younghee Jung1, Myung Jin Lee3, Hye-Yun Sin1, Nak-Hyun Kim3, Jeong-Hwan Hwang3, Jinyong Park3, Pyoeng Gyun Choe3,5, Wan Beom Park3,5, Eu Suk Kim1,5, Sang-Won Park5, Kyoung Un Park2,5, Hong Bin Kim1,5, Nam-Joong Kim3,5, Eui-Chong Kim4,5, Kyoung-Ho Song1,5* and Myoung-don Oh3,5

**Abstract**

**Background:** Healthcare-associated (HCA) infection has emerged as a new epidemiological category. The aim of this study was to evaluate the impact of HCA infection on mortality in community-onset *Klebsiella pneumoniae* bloodstream infection (*Kp*BSI).

**Methods:** We conducted a retrospective study in two tertiary-care hospitals over a 6-year period. All adult patients with *Kp*BSI within 48 hours of admission were enrolled. We compared the clinical characteristics of HCA and community-acquired (CA) infection, and analyzed risk factors for mortality in patients with community-onset *Kp*BSI.

**Results:** Of 553 patients with community-onset *Kp*BSI, 313 (57%) were classified as HCA-*Kp*BSI and 240 (43%) as CA-*Kp*BSI. In patients with HCA-*Kp*BSI, the severity of the underlying diseases was higher than in patients with CA-*Kp*BSI. Overall the most common site of infection was the pancreatobiliary tract. Liver abscess was more common in CA-*Kp*BSI, whereas peritonitis and primary bacteremia were more common in HCA-*Kp*BSI. Isolates not susceptible to extended-spectrum cephalosporin were more common in HCA-*Kp*BSI than in CA-*Kp*BSI (9% [29/313] vs. 3% [8/240]; p = 0.006). Overall 30-day mortality rate was significantly higher in HCA-*Kp*BSI than in CA-*Kp*BSI (22% [70/313] vs. 11% [27/240]; p = 0.001). In multivariate analysis, high Charlson’s weighted index of co-morbidity, high Pitt bacteremia score, neutropenia, polymicrobial infection and inappropriate empirical antimicrobial therapy were significant risk factors for 30-day mortality.

**Conclusions:** HCA-*Kp*BSI in community-onset *Kp*BSI has distinctive characteristics and has a poorer prognosis than CA-*Kp*BSI, but HCA infection was not an independent risk factor for 30-day mortality.

**Keywords:** *Klebsiella pneumoniae*, Bacteremia, Community-acquired infections, Healthcare-associated, Community-onset infection, Epidemiology
Background
Within the last decade, the concept of healthcare-associated (HCA) infection has been introduced, and HCA infection has been described as an epidemiological category different from both community-acquired (CA) and nosocomial infection [1,2]. Most importantly, mortality in HCA infection seems to be generally higher than that in CA infection, and similar to that in nosocomial infection [2-4]. However, there are conflicting results regarding whether HCA infection is an independent risk factor for mortality in bloodstream infection [1,5]. A few pathogens have been studied in terms of HCA infection with *S. aureus* dominating the research, and these studies reported inconsistent data concerning the impact of HCA infection on mortality [6-13]. For gram-negative bacteria, the data on the impact of HCA infection on mortality were conflicting, as well [9-12]. *Klebsiella pneumoniae* is one of the most important gram-negative bacteria clinically, and *K. pneumoniae* bloodstream infection (*Kp*BSI) has a mortality rate of about 20% [11,14-16]. Classically, *Kp*BSI was simply classified into CA and nosocomial infections depending on bacteremia onset time: within 48 hours and after 48 hours of admission, respectively, and the different characteristics of CA-*Kp*BSI versus nosocomial *Kp*BSI have been well evaluated [11,14,15,17,18]. CA-*Kp*BSI is usually associated with liver abscesses in patients with diabetes in East Asian countries, such as Korea and Taiwan [19-22]. On the other hand, nosocomial *Kp*BSI presents as primary bacteremia and/or pneumonia in patients with severe underlying diseases like malignancies. Thus, nosocomial infection has a higher mortality than CA infection [11,14,15,17,18]. However, there have been few studies of HCA-*Kp*BSI [11-13]. Therefore, we aimed to evaluate the impact of HCA infection on mortality and to compare the clinical characteristics of HCA and CA infection in patients with community-onset *Kp*BSI.

Methods
Study setting and patients
We conducted a retrospective study of the medical records of the patients with *Kp*BSI from January 2003 to December 2008 at Seoul National University Hospital (a 1,600-bed tertiary-care hospital, Seoul, Korea) and Seoul National University Bundang Hospital (a 900-bed tertiary-care hospital, Seongnam, Korea). All adult patients (≥18 year) who had *Kp*BSI within 48 hours of admission were enrolled. When there were multiple *Kp*BSI episodes only the first was included. We collected patient’s data on age, sex, underlying disease, site of infection, laboratory findings, microbiologic characteristics and treatment outcomes. To assess treatment outcomes we investigated 30-day mortality. This study was approved by the institutional review board of Seoul National University Hospital (IRB No. H-1010-062-336) and Seoul National University Bundang Hospital (IRB No. B-0910/086-004) according to the Helsinki Declaration.

Definitions
Community-onset *Kp*BSI was defined as *Kp*BSI occurring within 48 hours of admission. HCA-*Kp*BSI was defined when a patient had one of the following medical histories: (1) intravenous therapy at home or in an outpatient clinic within the previous 30 days; (2) renal dialysis in a hospital or clinic within the previous 30 days; (3) hospitalization for 2 or more days within the previous 90 days; (4) residence in a nursing home or long-term care facility for 2 or more days [1]. Patients without any of these factors were classified as CA-*Kp*BSI.

Biliary tract disease was defined when one or more complicated biliary stone was present, or there was a structural biliary abnormality due to benign or malignant disease. Chronic liver disease referred to chronic hepatitis and liver cirrhosis due to any cause. Charlson’s weighted index of co-morbidity and the Pitt bacteremia score were used to evaluate the severities of underlying disease and of acute illness, respectively [23,24]. Shock was defined as a decrease in systolic blood pressure to 90mmHg or less, or a decrease of at least 40mmHg below baseline blood pressure despite adequate fluid resuscitation [25]. An absolute neutrophil count of less than 500/mL was defined as neutropenia. Polymicrobial infection was defined when any pathogen other than *K. pneumoniae* was isolated from blood culture at the same time as the *K. pneumoniae*, and the isolated pathogen also had clinical significance. Infection focus was assessed clinically by attending physician in accordance with site of isolation of *K. pneumoniae*.

The empirical antimicrobial therapy was defined as the initial antibiotic choice before the results of blood culture and antimicrobial susceptibility tests were available, and the definitive antimicrobial therapy was defined as the antibiotic choice after the report of microbiologic tests. *K. pneumoniae* which was not susceptible to either cefotaxime or ceftazidime was considered as ‘suspected extended-spectrum beta-lactamase (ESBL) producing *K. pneumoniae*’. Antimicrobial therapy was considered as ‘inappropriate’ when the treatment regimen did not include any antibiotic active in vitro. In addition 3rd generation cephalosporin monotherapy for ‘suspected ESBL-producing *K. pneumoniae*’ was considered ‘inappropriate’, regardless of the results of antibiotic susceptibility tests.

Microbiological analysis
All isolates were defined by BacT/ALERT FA and FN (bioMe’rieux, Durham, North Carolina). Antimicrobial susceptibility was identified by disk diffusion tests from
Table 1 Clinical characteristics of community-acquired and healthcare-associated infections in patients with community-onset Klebsiella pneumoniae bloodstream infection

|                             | CA-KpBSI (n = 240) | HCA-KpBSI (n = 313) | p   |
|-----------------------------|---------------------|----------------------|-----|
| Age (years) (mean ±SD)      | 63.0 (±13.6)        | 60.3 (±12.9)         | 0.015 |
| Male sex                    | 142 (59.2)          | 206 (65.8)           | 0.124 |
| Underlying disease          |                     |                      |     |
| Diabetes mellitus           | 74 (30.8)           | 71 (22.7)            | 0.031 |
| Chronic liver disease       | 39 (16.3)           | 84 (26.8)            | 0.003 |
| Biliary tract disease       | 42 (17.5)           | 43 (13.7)            | 0.224 |
| Chronic kidney disease      | 13 (5.4)            | 19 (6.1)             | 0.774 |
| Respiratory disease         | 18 (7.5)            | 21 (6.7)             | 0.719 |
| Solid tumor                 | 58 (24.2)           | 180 (57.5)           | <0.001 |
| Hematologic malignancy      | 4 (1.7)             | 27 (8.6)             | 0.002 |
| Solid organ transplantation  | 5 (2.1)             | 9 (2.9)              | 0.557 |
| Charlson’s WIC (23)         | 47 (19.6)           | 141 (45.0)           | <0.001 |
| Primary infection site      |                     |                      |     |
| Urinary tract               | 31 (12.9)           | 34 (10.9)            | 0.457 |
| Peritoneum                  | 11 (4.6)            | 46 (14.7)            | <0.001 |
| Pancreatobiliary tract      | 82 (34.2)           | 102 (32.6)           | 0.696 |
| Liver                       | 67 (27.9)           | 41 (13.1)            | <0.001 |
| Lung                        | 16 (6.7)            | 28 (8.9)             | 0.326 |
| Skin and soft tissue        | 4 (1.7)             | 8 (2.6)              | 0.477 |
| Bone                        | 4 (1.7)             | 2 (0.6)              | 0.411 |
| Central nervous system      | 1 (0.4)             | 0 (0)                | 0.434 |
| Others                      | 1 (0.4)             | 3 (1.0)              | 0.637 |
| Unknown                     | 21 (8.8)            | 52 (16.6)            | 0.007 |
| Metastatic infection        | 11 (4.6)            | 9 (2.9)              | 0.286 |
| Endophthalmitis             | 5 (2.1)             | 3 (1.0)              | 0.303 |
| Pitt bacteremia score (24)  | 36 (15.0)           | 56 (17.9)            | 0.366 |
| Shock at presentation       | 55 (22.9)           | 101 (32.3)           | 0.015 |
| Neutropenia at presentation | 3 (1.3)             | 42 (13.4)            | <0.001 |
| Polymicrobial infection     | 34 (14.2)           | 47 (15.0)            | 0.780 |
| Initial antimicrobial regimen |                     |                      |     |
| Piperacillin-tazobactam     | 9 (3.8)             | 30 (9.6)             | 0.008 |
| Quinolone                   | 23 (9.6)            | 18 (5.8)             | 0.088 |
| 1st generation cephalosporin| 2 (0.8)             | 0 (0)                | 0.188 |
| 3rd generation cephalosporin| 173 (72.1)          | 186 (59.4)           | 0.002 |
| Carbapenem                  | 30 (12.5)           | 48 (15.3)            | 0.342 |
| Inappropriate empirical antimicrobial therapy | 14 (5.8) | 26 (8.3) | 0.266 |
| Inappropriate definitive antimicrobial therapy | 7/223 (3.1) | 7/278 (2.5) | 0.675 |
| 30-day mortality            | 27 (11.3)           | 70 (22.4)            | 0.001 |

Data indicate no. (%) of patients. WIC, weighted index of co-morbidity; CA-KpBSI, community-acquired Klebsiella pneumoniae bloodstream infection; HCA-KpBSI, healthcare-associated Klebsiella pneumoniae bloodstream infection. * Others were one appendicitis, one pericarditis and two periodontitis. ** 52 patients were excluded from the analysis (15 patients were transferred to other hospitals and 37 died before the culture results were available).

2003 to 2006, and by Microscan WalkAway-96 (Siemens Healthcare Diagnostics, Deerfield, Illinois) from 2007 to 2008, using the criteria of the Clinical and Laboratory Standards Institute (CLSI; formerly, National Committee for Clinical Laboratory Standards) guidelines. For the available ‘suspected ESBL-producing K. pneumoniae’ isolates, ESBL production was determined by the double disk synergy test according to the CLSI performance standards [26].

Statistical analysis
Student’s t-test was used to compare continuous variables and the χ² test or Fisher’s exact test was used to compare categorical variables. To identify independent risk factors for 30-day mortality, a stepwise logistic regression model was used. Risk factors with a p value <0.10 in the univariate analysis for 30-day mortality were included in the initial model, and forward stepwise selection was performed to develop the final model. We included the Pitt bacteremia score instead of shock and, the Charlson’s weighted index of co-morbidity instead of underlying diseases to avoid data overlap in the multivariate analysis. p <0.05 was considered statistically significant. PASW for Windows (version 18 software package; SPSS Inc., Chicago, IL, USA) was used for all analyses.

Results
Demographics and underlying diseases
592 patients with community-onset KpBSI were identified in the 6-year period. Of these, 553 (93%) were analyzed, because 34 patients were lost to follow-up and medical record was not available in 5 patients. Of the 553 patients with community-onset KpBSI, 313 (57%) were classified as HCA-KpBSI and 240 (43%) as CA-KpBSI. The mean age of the 553 patients was 61 years (median: 63 years, range: 18–103), and 348 (63%) of the patients were male. Solid tumor was the most common underlying disease (238 patients, 43%). 145 (26%) patients had diabetes mellitus and 123 (22%) had chronic liver disease.

The demographics and underlying diseases of HCA-KpBSI and CA-KpBSI are listed in Table 1. Solid tumor (58% vs 24%; p <0.001), hematologic malignancy (7% vs 2%; p = 0.002) and chronic liver disease (27% vs 16%; p = 0.003) were more common in HCA-KpBSI than in CA-KpBSI. Diabetes mellitus (31% vs 23%; p = 0.031) was more common in CA-KpBSI than in HCA-KpBSI.

Primary sites of infection and treatment outcomes
The pancreatobiliary tract was the most common site of infection (184 cases, 33%). Liver (108, 20%) and primary bacteremia (unknown focus) (73, 13%) were also frequent sites of infection. Initially 156 (28%) patients presented shock and 45 (8%) had neutropenia. 40 (7%) patients of the 553 patients were treated with...
inappropriate empirical antimicrobial therapy. After excluding 52 of the 553 patients (15 were transferred to other hospitals and 37 died before the culture results were reported), 14 of the remaining 501 patients (3%) were found to have been treated with inappropriate definitive antimicrobial therapy.

The primary sites of infection and treatment outcomes of HCA-KpBSI and CA-KpBSI are also compared in Table 1. Peritonitis (15% vs. 5%; \( p < 0.001 \)) and primary bacteremia (17% vs. 9%; \( p = 0.007 \)) were more common in HCA-KpBSI than in CA-KpBSI. On the other hand, liver abscess (28% vs. 13%; \( p < 0.001 \)) was more frequent in CA-KpBSI than in HCA-KpBSI. Initial shock (32% vs. 23%; \( p = 0.015 \)) and neutropenia (13% vs. 1%; \( p < 0.001 \)) were more common in HCA-KpBSI than in CA-KpBSI. The 30-day mortality of HCA-KpBSI was higher than that of CA-KpBSI (22% vs. 11%; \( p = 0.001 \)).

**Antimicrobial susceptibility**

48 of the 553 isolates (9%) were not susceptible to ciprofloxacin and 37 isolates (7%) were not susceptible to either cefotaxime or ceftazidime. Of these 37 isolates, 27 were available for ESBL confirmatory tests and we performed the double disk synergy test on them. Eighteen were confirmed as producing ESBL. The antimicrobial susceptibilities of HCA-KpBSI and CA-KpBSI are compared in Table 2. A significantly higher proportion of the HCA-KpBSI than of the CA-KpBSI was resistant to tested antimicrobial agents other than imipenem and amikacin.

**Risk factors for 30-day mortality**

The results of the univariate analyses of risk factors for 30-day mortality are shown in Table 3. High Charlson’s weighted index of co-morbidity was a risk factor (odds ratio [OR], 2.86; 95% confidence interval [CI], 1.83-4.88) and, when we analyzed each underlying disease, solid tumor (OR, 3.32; 95% CI, 2.09-5.28) and hematologic malignancy (OR, 3.52; 95% CI, 1.58-7.84) also turned out to be significant risk factors. Infections of unknown origin (OR, 3.71; 95% CI, 2.17-6.34) and respiratory infections (OR, 3.38; 95% CI, 1.76-6.48) developed more frequently in non-survivors than in survivors. In contrast, liver abscess (OR, 0.11; 95% CI, 0.03-0.35) and pancreatic-biliary infection (OR, 0.50; 95% CI, 0.30-0.84) were more common in survivors than in non-survivors. In addition, high Pitt bacteremia score (OR, 8.04; 95% CI, 4.87-13.28), neutropenia at initial presentation (OR, 4.48; 95% CI, 2.37-8.46), inappropriate empirical antimicrobial therapy (OR, 2.46; 95% CI, 1.22-4.96), polymicrobial infection (OR, 2.30; 95% CI, 1.34-3.94) and healthcare-associated infection (OR, 2.27; 95% CI, 1.41-3.68) were risk factors in univariate analyses. There was no significant difference in rates of antimicrobial resistance to ciprofloxacin (7.0% in survivors vs. 9.3% in non-survivors; \( p = 0.440 \)) and extended-spectrum cephalosporin (6.4% in survivors vs. 8.2% in non-survivors; \( p = 0.499 \)) between survivors and non-survivors.

From the multivariate logistic regression analysis, significant risk factors for 30-day mortality were high (≥3) Charlson’s weighted index of co-morbidity (adjust odds ratio [aOR], 3.23; 95% CI, 1.88-5.57), high (≥4) Pitt bacteremia score (aOR, 8.43; 95% CI, 4.70-15.11), neutropenia (aOR, 2.60; 95% CI, 1.24-5.48), polymicrobial infection (aOR, 2.36; 95% CI, 1.21-4.60) and inappropriate empirical antimicrobial therapy (aOR, 2.43; 95% CI, 1.07-

### Table 2 Comparison of the antimicrobial susceptibility of community-acquired (CA) and healthcare-associated (HCA) *Klebsiella pneumoniae* bloodstream infection (KpBSI)

| Antibiotics                  | CA-KpBSI (n = 240) (Non-susceptible/T (%)) | HCA-KpBSI (n = 313) (Non-susceptible/T (%)) | \( p \) |
|-----------------------------|-------------------------------------------|-------------------------------------------|-------|
| Ciprofloxacin               | 12/240 (5.0)                              | 36/313 (11.5)                             | 0.007 |
| Extended-spectrum cephalosporin | 8/240 (3.3)                             | 29/313 (9.3)                             | 0.006 |
| Cefotaxime                  | 8/240 (3.3)                               | 25/313 (8.0)                             | 0.022 |
| Ceftazidime                 | 6/240 (2.5)                               | 25/313 (8.0)                             | 0.005 |
| ESBL-production\(^a\)       | 2/237 (0.8)                               | 16/310 (5.2)                             | 0.006 |
| Piperacillin plus tazobactam | 6/239 (2.5)                               | 19/311 (6.1)                             | 0.045 |
| Aztreonam                   | 5/175 (2.9)                               | 26/253 (11.1)                            | 0.004 |
| Imipenem                    | 1/240 (0.4)                               | 1/313 (0.3)                              | 1.000 |
| Amikacin                    | 7/240 (2.9)                               | 17/313 (5.4)                             | 0.150 |
| Gentamicin                  | 6/240 (2.5)                               | 22/313 (7.0)                             | 0.016 |
| Tobramycin                  | 7/177 (4.0)                               | 26/253 (10.3)                            | 0.015 |

Data indicate number of non-susceptible isolates/total number of tested isolates (%). \( T \), total number of tested isolates; ESBL, extended-spectrum beta-lactamase.

\(^a\) 5 isolates among the CA-KpBSI were available for ESBL confirmatory tests and 14 among the HCA-KpBSI.
Liver abscess (aOR, 0.17; 95% CI, 0.05-0.58) and pancreatobiliary tract infection (aOR, 0.42; 95% CI, 0.23-0.79) were found to be protective factors (Table 4). HCA infection was not an independent risk factor for mortality in multivariate analysis (aOR, 1.27; 95% CI, 0.70-2.30).

Discussion

In a previous study, we demonstrated that nosocomial KpBSI was different from CA- KpBSI [18]. However, the healthcare system has changed dramatically and this simple dichotomy is no longer appropriate for KpBSI in

| Risk Factor                          | No. of survivors (n = 456) | No. of non-survivors (n = 97) | OR (95% CI) | p      |
|--------------------------------------|----------------------------|-------------------------------|-------------|--------|
| Age (year) (mean ±SD)                | 61.1 (±13.5)               | 63.3 (±12.1)                  | 1.00 (0.63-1.57) | 0.992  |
| Male sex                             | 287 (62.9)                 | 61 (62.9)                     | 1.00 (0.63-1.57) | 0.992  |

Underlying disease

- Diabetes mellitus: 128 (28.1) vs. 17 (17.5) (aOR, 0.55; 95% CI, 0.31-0.96) (p = 0.032)
- Chronic liver disease: 94 (20.6) vs. 29 (29.9) (aOR, 1.64; 95% CI, 1.01-2.68) (p = 0.046)
- Biliary tract disease: 77 (16.9) vs. 8 (8.2) (aOR, 0.44; 95% CI, 0.21-0.95) (p = 0.032)
- Chronic kidney disease: 28 (6.1) vs. 4 (4.1) (aOR, 0.66; 95% CI, 0.26-1.92) (p = 0.440)
- Respiratory disease: 34 (7.5) vs. 5 (5.2) (aOR, 0.68; 95% CI, 0.26-1.77) (p = 0.421)
- Solid tumor: 173 (37.9) vs. 65 (67.0) (aOR, 3.32; 95% CI, 2.09-5.28) (p < 0.001)
- Hematologic malignancy: 16 (3.5) vs. 11 (11.3) (aOR, 3.52; 95% CI, 1.58-7.84) (p = 0.003)
- Solid organ transplantation: 13 (2.9) vs. 1 (1.0) (aOR, 0.36; 95% CI, 0.05-2.75) (p = 0.482)

Primary infection site

- Urinary tract: 58 (12.7) vs. 7 (7.2) (aOR, 0.53; 95% CI, 0.24-1.22) (p = 0.126)
- Peritoneum: 42 (9.2) vs. 15 (15.5) (aOR, 1.80; 95% CI, 0.96-3.40) (p = 0.066)
- Pancreatobiliary tract: 163 (35.7) vs. 21 (21.6) (aOR, 0.50; 95% CI, 0.30-0.84) (p = 0.007)
- Liver: 105 (23.0) vs. 3 (3.1) (aOR, 0.11; 95% CI, 0.03-0.35) (p < 0.001)
- Lung: 27 (5.9) vs. 17 (17.5) (aOR, 3.38; 95% CI, 1.76-6.48) (p < 0.001)
- Skin and soft tissue: 8 (1.8) vs. 4 (4.1) (aOR, 2.41; 95% CI, 0.71-8.17) (p = 0.239)
- Bone: 5 (1.1) vs. 1 (1.0) (aOR, 0.94; 95% CI, 0.11-8.13) (p = 1.000)
- Central nervous system: 1 (0.2) vs. 0 (0) (aOR, 0.82; 95% CI, 0.79-0.86) (p = 1.000)
- Others\(a\): 3 (0.7) vs. 1 (1.0) (aOR, 1.57; 95% CI, 0.16-15.28) (p = 0.539)
- Unknown: 45 (9.9) vs. 28 (28.9) (aOR, 3.71; 95% CI, 2.17-6.34) (p < 0.001)

Metastatic infection: 18 (3.9) vs. 2 (2.1) (aOR, 0.51; 95% CI, 0.12-2.25) (p = 0.551)
- Endophthalmitis: 8 (1.8) vs. 0 (0) (aOR, 0.82; 95% CI, 0.79-0.86) (p = 0.362)
- Pitt bacteremia score (≥4): 46 (10.1) vs. 46 (47.4) (aOR, 8.04; 95% CI, 4.87-13.28) (p < 0.001)
- Shock at presentation: 97 (21.3) vs. 59 (60.8) (aOR, 5.75; 95% CI, 3.61-9.15) (p < 0.001)
- Neutropenia at presentation: 25 (5.5) vs. 20 (20.6) (aOR, 4.48; 95% CI, 2.37-8.46) (p < 0.001)
- Healthcare-associated infection: 243 (53.3) vs. 70 (72.2) (aOR, 2.27; 95% CI, 1.41-3.68) (p = 0.001)
- Polymicrobial infection: 57 (12.5) vs. 24 (24.7) (aOR, 2.30; 95% CI, 1.34-3.94) (p = 0.002)

Antimicrobial resistance

- non-susceptible to CIP: 32 (7.0) vs. 9 (9.3) (aOR, 1.36; 95% CI, 0.63-2.94) (p = 0.440)
- non-susceptible to ESC: 29 (6.4) vs. 8 (8.2) (aOR, 1.32; 95% CI, 0.59-2.99) (p = 0.499)

Inappropriate empirical antimicrobial therapy: 27 (5.9) vs. 13 (13.4) (aOR, 2.46; 95% CI, 1.22-4.96) (p = 0.010)

Inappropriate definitive antimicrobial therapy\(b\): 12/446 (2.7) vs. 2/55 (3.6) (aOR, 1.37; 95% CI, 0.30-6.26) (p = 0.659)

Data indicate no. (%) of patients.

\(WIC\), weighted index of co-morbidity; CIP, ciprofloxacin; ESC, extended-spectrum cephalosporin; OR, odds ratio; CI, confidence interval.

\(a\) Others were one appendicitis, one pericarditis and two periodontitis.

\(b\) 52 patients were excluded from the analysis (15 patients were transferred to other hospitals and 37 died before the culture results were available).
the current clinical setting. In this study we showed that HCA-KpBSI accounted for over 50% of community-onset KpBSI and HCA-KpBSI had different clinical characteristics from CA-KpBSI in terms of underlying disease, infection focus, antimicrobial susceptibility and treatment outcome. To our knowledge, this is the largest multicenter study comparing the clinical characteristics of HCA-KpBSI and CA-KpBSI [11,12].

Cancer was the most common associated condition in HCA-KpBSI. In contrast, diabetes mellitus was the most common associated condition in CA-KpBSI. The distribution of underlying disease in HCA-KpBSI was similar to that in nosocomial KpBSI, except for the frequency of chronic liver disease. While we found previously that the frequency of this disease did not differ between CA-KpBSI and nosocomial KpBSI [18], it was more common in HCA-KpBSI than in CA-KpBSI (27% vs. 16%; \( p = 0.003 \)) in the present study. The latter finding is similar to that of a study performed in Taiwan, although in the Taiwanese study the difference was not statistically significant (liver cirrhosis in HCA-KpBSI [14.0%] vs. CA-KpBSI [10.6%]; \( p = 0.339 \)) [12].

The primary site of infection was identified in 87% of community-onset KpBSI. The most common source was the pancreatobiliary tract (33%), followed by liver abscess (20%). Liver abscess was more frequent in CA-KpBSI than in HCA-KpBSI. Compared to nosocomial KpBSI, in which liver abscess was very rare (0% to 2%) [11,14,18], HCA-KpBSI was quite frequently associated with liver abscess (13%). Peritonitis was fairly frequent (>10%), more so in HCA-KpBSI than in CA-KpBSI in our analysis; in contrast Wu et al. found only a few (<5%) of intra-abdominal infection and no difference in frequency between HCA-KpBSI and CA-KpBSI [12]. Our higher frequency of peritonitis may be due to the prevalence of chronic liver disease caused by hepatitis B or C virus in Korea, which increases the occurrence of spontaneous bacterial peritonitis [27,28].

More of the HCA-KpBSI isolates than of the CA-KpBSI isolates were resistant to antimicrobial agents. Over 10% of the former were not susceptible to ciprofloxacin and 9% were not susceptible to one of the extended-spectrum cephalosporin. Although frequent antimicrobial resistance could affect the inadequacy of the initial choice of antimicrobial agent, there was no difference in rate of inappropriate empirical antimicrobial therapy between the HCA-KpBSI and CA-KpBSI (6% vs. 8%; \( p = 0.266 \)). This result could have arisen because in cases of healthcare-associated infection clinicians may have taken into account frequencies of antimicrobial resistance when selecting the initial antibiotic. Actually, fewer HCA-KpBSI than CA-KpBSI (6% vs. 10%; \( p = 0.088 \)) were started on quinolones while more were started on piperacillin-tazobactam (Table 1).

Regarding empirical treatment, the proportion of patients treated inappropriately (7.2% of total patients) was much lower than was observed in other studies, which showed that over 20% of patients were treated inappropriately [9,29,30]. This discrepancy might have been the result of differences in the definition of ‘appropriate empirical treatment’; because the definition we used was less strict than those in other studies [31-33]. In addition, broad-spectrum antimicrobial agents, such as 3rd generation cephalosporins or carbapenems, were frequently used empirically in our study (84.6% in CA infection, 74.7% in HCA infection). Considering that only 3.3% of organisms in CA infection and 9.3% of organisms in HCA infection were non-susceptible to extended-spectrum cephalosporins, the use of broad-spectrum antimicrobial agents also might have influenced the lower proportion of patients with treated inappropriately. However, other East Asian studies of K. pneumoniae bacteremia also demonstrated a similar proportion of patients treated with inappropriate empirical therapy [12,14,18].

There was a significant difference of 30-day mortality rate between HCA-KpBSI and CA-KpBSI in this study (22% vs. 11%; \( p = 0.001 \)). High Charlson’s weighted index of co-morbidity (≥3), high Pitt bacteremia score (≥4), neutropenia, polymicrobial infection and inappropriate empirical antimicrobial therapy were found to be

Table 4 Significant risk factors for 30-day mortality among community-onset Klebsiella pneumoniae bloodstream infection in multivariate analysis

| Risk Factor                               | No. of survivors (n = 456) | No. of non-survivors (n = 97) | Adjusted OR (95% CI) | \( p \) |
|------------------------------------------|----------------------------|--------------------------------|----------------------|--------|
| Charlson’s WIC (≥3)                      | 135 (29.6)                 | 53 (54.6)                      | 3.23 (1.88-5.57)     | <0.001 |
| Pitt bacteremia score (≥4)               | 46 (10.1)                  | 46 (47.4)                      | 8.43 (4.70-15.11)    | <0.001 |
| Neutropenia                              | 25 (5.5)                   | 20 (20.6)                      | 2.60 (1.24-5.48)     | 0.012  |
| Polymicrobial infection                  | 57 (12.5)                  | 24 (24.7)                      | 2.36 (1.21-4.60)     | 0.012  |
| Pancreatobiliary infection               | 163 (35.7)                 | 21 (21.6)                      | 0.42 (0.23-0.79)     | 0.006  |
| Liver abscess                            | 105 (23.0)                 | 3 (3.1)                        | 0.17 (0.05-0.58)     | 0.038  |
| Inappropriate empirical antimicrobial therapy | 27 (5.9)                  | 13 (13.4)                      | 2.43 (1.07-5.52)     | 0.025  |

Data indicate no. (%) of patients. OR, odds ratio; CI, confidence interval.
independent risk factors for mortality. However, HCA infection itself was not a significant risk factor for 30-day mortality in multivariate analysis. This finding is consistent with the recent report from Taiwan and a bloodstream infection study dealing with gram-negative bacteria [9,12]. There are several explanations for this result. First, in our study, underlying disease and acute illness, which are classical risk factors for outcome of infectious disease, may have been so severe as to have attenuated the effect of HCA infection on mortality [23,24,34]. Second, whether the infection focus was removable, and was or was not removed, may have affected mortality more than whether the infection was HCA or not [35]. Liver abscess and pancreatobiliary infection can be classified as infections with removable foci, as opposed to pneumonia or primary bacteremia. In our study, percutaneous or internal drainage was performed in cases of liver abscess and obstructive pancreatobiliary infection, and these kinds of infection were found to be independent protective factors for mortality, as in the previous studies [11,14,18]. Third, as indicated by Friedman et al., the definition of HCA infection which we used in this study may have been excessively broad since the definition was based on the U.S. medical system [1]. Unlike the U.S., South Korea has started a national health insurance system in 1977 and extended it nationwide in 1982. Consequently, there is a tendency for more people to access the medical system and be classified as HCA infection in Korea. Such national differences in healthcare systems could complicate the unambiguous identification of patients with HCA infections so as to be able to evaluate the actual effect of HCA infection on mortality. Therefore we need further studies using a more accurate and consistent definition of HCA infection that accords better with variations in clinical practice.

Our study had several limitations. First, there was a potential bias because it was performed retrospectively. Second, it was conducted in tertiary-care and university-affiliated hospitals and there was a large proportion of cancer patients in both the CA-KpBSI and HCA-KpBSI groups. Hence, we cannot extrapolate our result to community-based institutions. Third, we did not evaluate the ‘attributable’ mortality due to KpBSI, so that some of the deaths in our study may not have been related to KpBSI. However, efforts to designate outcomes as ‘attributable’ to infection are often subjective and inconsistent. We therefore employed an unambiguous definition, namely 30-day mortality rate, for evaluating treatment outcomes. Fourth, because we did not review the patients’ previous exposure to antimicrobial agents, we could not determine the influence of that factor on the acquiring resistant organisms and treatment outcome. Additionally, we did not collect data on the variation of antimicrobial therapy, such as duration or dosage; therefore, we could not take into account these issues, which could affect the analysis of risk factors for mortality. However, upon examining the mortality rate in other studies, our data are comparable; therefore, the regimen and duration of therapy we used were also likely to be similar to others [12,14].

What clinicians actually want to know is that HCA infection needs a specific work-up process or treatment. Accordingly, our study can provide useful information. First, we could see the difference of infection focus according to the epidemiological category more clearly by separating HCA infection and CA infection in comparison to our previous report [18]. Peritonitis is more commonly associated with HCA infection than with CA infection in the present study, while the frequency of peritonitis in CA infection was relatively high (20.4%) and was not different from that observed in nosocomial infection in the previous study [18]. However, when we classified more precisely we could see that peritonitis occurred in much lower frequency in true CA infection. In addition, we could identify the infection focus of all but 8.8% of the patients with true CA infection (in previously defined CA infection, 25.7% patients were unidentified for infection focus) [18]. Second, comparing the resistance rate to antimicrobial agents in HCA infection with CA infection can help clinicians choose an initial antimicrobial agent in treating patients of each subset, which means not only should we consider broad-spectrum antimicrobial agents in HCA infection but also that we may not need to start broad-spectrum antimicrobial agents, such as extended-spectrum cephalosporins or carbapenems, in CA infection. Based on our data, quinolone can be a drug of choice in treating true CA-KpBSI. Finally, even though we showed many differences between HCA infection and CA infection, we did not find HCA infection to be an independent risk factor for mortality in KpBSI, which confirmed that the already known risk factors for mortality (severity of underlying disease, inadequate empirical therapy and severity of acute illness) are more important predictors of mortality in KpBSI [12,14].

**Conclusion**

HCA-KpBSI represented over half of community-onset KpBSI and had different characteristics from CA-KpBSI. In HCA-KpBSI, underlying diseases were more severe, primary bacteremia and peritonitis were more common and resistance to antimicrobials was more frequent than in CA-KpBSI. HCA-KpBSI had higher 30-day mortality than CA-KpBSI, but HCA infection was not an independent risk factor for 30-day mortality. In present-day clinical circumstances, HCA-KpBSI should be identified...
as a distinctive category and be approached in a different way from CA-KpBSI.

Competing interests
There are no potential conflicts of interest for any authors.

Authors’ contribution
All authors conceived of the study. YHI, MJL, HYS collected the data. KHS and YHJ carried out data analysis and interpretation. NHK, JHJ, JYP, PGC, WBP, ESK, SWP, KUP, HBK, NJK, ECK and MDO carried out data interpretation. YHJ and KHS drafted the manuscript. All authors have read and approved the final manuscript.

Acknowledgement
This study was supported by grant No. 11-2009-012 from the Seoul National University Bundang Hospital Research Fund. This study was presented in part at the 49th annual meeting of the Infectious Diseases Society of America, Boston, 2011 (Abstract number 990).

Author details
1 Department of Internal Medicine, Seoul National University Bundang Hospital, 173 Gumi-ro, Bundang-gu, Seongnam 463-707, Republic of Korea.
2 Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. 3 Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
3 Department of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea.
4 Seoul National University College of Medicine, Seoul, Korea.
5 Seoul National University Hospital, Seoul, Korea.

Received: 17 March 2012 Accepted: 27 September 2012
Published: 3 October 2012

References
1. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, et al: Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002, 137:971–979.
2. Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH: Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database. Crit Care Med 2006, 34:2588–2598.
3. Valles J, Calbo E, Anoro E, Fontanals D, Xercavins M, Espejo E, Serrate G, Freixa N, Morera MA, Font B, et al: Bloodstream infections in adults: importance of healthcare-associated infections. J Infect 2008, 56:27–34.
4. Kollef MH, Ziberman MD, Shorr AF, Vo L, Schein J, Mieke ST, Kim M: Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: a multicenter cohort study. J Infect 2011, 62:130–135.
5. Lenz R, Leal JR, Church DL, Gregson DB, Ross T, Laupland KB: The distinct category of healthcare associated bloodstream infections. BMC Infect Dis 2012, 12:85.
6. Liao CH, Chen SY, Chang SC, Hsuah PR, Hung CC, Chen YC: Characteristics of community-acquired and health care-associated Staphylococcus aureus bacteremia in patients treated at the emergency department of a teaching hospital. Diagn Microbiol Infect Dis 2005, 53:85–92.
7. Lesens O, Hansmann Y, Brannigan E, Hopkins S, Meyer P, O’Connell B, Prevost G, Bergin C, Christmann DJ: Healthcare-associated Staphylococcus aureus bacteremia and the risk for methicillin resistance: is the Centers for Disease Control and Prevention definition for community-acquired bacteremia still appropriate? Infect Control Hosp Epidemiol 2005, 26:204–209.
8. Piatagia M, Kleinman LC, de la Cruz EG, L Jenkins SG: Predicting risk for death from MRSA bacteremia (1). Emerg Infect Dis 2012, 18:1072–1080.
9. Marshall J, Fraser VJ, Doherty J, Warren DK, Between Community and Hospital: Healthcare-associated Gram-Negative Bacteremia among Hospitalized Patients. Infect Control Hosp Epidemiol 2009, 30:1050–1056.
10. Cheong HS, Kang CI, Kwon KT, Heo ST, WY, Kim ES, Lee JS, Ko KS, Chung DR, Lee NY, et al: Clinical significance of community-acquired infections in community-onset Escherichia coli bacteremia. J Antimicrob Chemother 2007, 60:1355–1360.
11. Meatherall BL, Gregson D, Ross T, Piotou JD, Laupland KB: Incidence, risk factors, and outcomes of Klebsiella pneumoniae bacteremia. Am J Med 2009, 122:866–873.
12. Wu HS, Wang FD, Tseng CP, Wu TH, Lin YT, Fung CP: Characteristics of healthcare-associated and community-acquired Klebsiella pneumoniae bacteremia in Taiwan. J Infect 2012, 64:162–168.
13. Sun HY, Chen SY, Chang SC, Pan SC, Su CP, Chen YC: Community-onset Escherichia coli and Klebsiella pneumoniae bacteremia: influence of health care exposure on antimicrobial susceptibility. Diagn Microbiol Infect Dis 2006, 55:135–141.
14. Tsay RW, Su IK, Fung CP, Chang FY: Characteristics of bacteremia between community-acquired and nosocomial Klebsiella pneumoniae infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Arch Intern Med 2012, 162:1021–1027.
15. Yinnon AM, Butnaru A, Raveh D, Jerassy Z, Rubensky B: Klebsiella bacteremia: community versus nosocomial infection. JIMM 1996, 89:933–941.
16. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Kugiman KP, Bonomo RA, et al: International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 2004, 140:26–32.
17. Watanakunakorn C, Jara J: Klebsiella bacteremia: a review of 196 episodes during a decade (1980–1989). Scand J Infect Dis 1991, 23:399–405.
18. Kang CJ, Kim SH, Bang JW, Kim HB, Kim NJ, Kim EC, Oh MD, Cho KW: Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance. J Korean Med Sci 2006, 21:816–822.
19. Wang JH, Liu YC, Lee SS, Yen MY, Chen YS, Wann SR, Lin HH: Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis 1998, 26:1434–1438.
20. Chung DR, Lee SS, Lee HR, Kim HB, Choi HJ, Eom JS, Kim JS, Choi YH, Lee JS, Chung MH, et al: Emerging invasive liver abscess caused by K1 serotype Klebsiella pneumoniae in Korea. J Infect 2007, 54:578–583.
21. Fung CP, Chang FY, Lee SC, Hu BS, Kuo BI, Liu CY, Ho M, Siu UK: A global emerging disease of Klebsiella pneumoniae liver abscess: is serotype K1 an important factor for complicated endophthalmitis? Q J 2010, 50:420–424.
22. Kim JK, Chung DR, Wie SH, Yoo JH, Park SW: Risk factor analysis of invasive liver abscess caused by the K1 serotype Klebsiella pneumoniae. Eur J Clin Microbial Infect Dis 2009, 28:109–111.
23. Charlton ME, Pompei P, Alex KL, MacKenzie EA: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373–383.
24. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MW, Miyashiro DK, Yu VL: Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991, 115:585–590.
25. Dellingfer RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhardt K, Angus DC, Brun-Buisson C, Beale R, et al: Surviving Sepsis Campaign International guidelines for management of severe sepsis and septic shock 2008: Crit Care Med 2008, 36:296–327.
26. Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicrobial susceptibility testing. Seventh informational supplement. CLSI document M100-S17. Wayne: CLSI 2007.
27. Chae HB, Kim JH, Kim JK, Yim H: Current status of liver diseases in Korea: hepatitis B, Korea J Hepatol 2009, 15(Suppl):S13–S24.
28. Shin HR: Epidemiology of hepatitis C virus in Korea. Intervirology 2006, 49:18–22.
29. McDonald JR, Friedman ND, Stout JE, Sexton DJ, Kaye KS: Risk factors for ineffective therapy in patients with bloodstream infection. Arch Intern Med 2005, 165:308–313.
30. Sun JS, Song JH, Ko KS, Yeom JS, Ki HK, Kim SW, Chang HH, Ryu SY, Kim YS, Jung SK, et al: Bloodstream infections and clinical significance of healthcare-associated bacteremia: a multicenter surveillance study in Korean hospitals. J Korean Med Sci 2010, 25:992–998.
31. Ibrahim EK, Sherman G, Ward S, Fraser VJ, Kollef MH: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146–155.
32. Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM: The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003, 9:412–418.

33. Song KH, Jeon JH, Park WB, Park SW, Kim HB, Oh MD, Lee HS, Kim NJ, Choe KW: Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case–control study. BMC Infect Dis 2009, 9:1.

34. Oltean S, TT D, Bondor C, Slavcovici A, Cismaru C, Lupse M, Muntean M, Jianu C, Marcu C, Oltean M: Charlson’s weighted index of comorbidities is useful in assessing the risk of death in septic patients. J Crit Care 2012, 27:370–375.

35. Kim SH, Park WB, Lee KD, Kang CJ, Kim HB, Oh MD, Kim EC, Choe KW: Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis 2003, 37:794–799.

doi:10.1186/1471-2334-12-239
Cite this article as: Jung et al.: Differences in characteristics between healthcare-associated and community-acquired infection in community-onset Klebsiella pneumoniae bloodstream infection in Korea. BMC Infectious Diseases 2012 12:239.